WHAT IS CLAIMED IS:

1. A compound represented by formula I:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

a and b are independently selected from the integers 0 and 1, such that the sum of a and b is 0 or 1;

X is selected from CH₂ and C(O);

R¹ is selected from the group consisting of:

- (1) C₁₋₁₅ alkyl optionally substituted with up to five groups as follows: (a) 1-3 OH groups; (b) 1 oxo group; (c) 1-5 halo groups, up to a perhaloalkyl group; (d) 1-3 C₁₋₆ alkoxy groups optionally substituted with up to five halo or a perhaloalkoxy, or up to 2 hydroxy or CO₂R⁶ groups; (e) 1-2 CO₂R⁶ groups and (f) 1-2 phenyl groups, each optionally substituted as follows: 1-5 halo groups, (2) 1-2 OH, CO₂R⁶, CN or S(O)_pR⁵ groups, and (3) 1-2 C₁₋₆ alkyl or alkoxy groups, each optionally substituted with 1-5 halo, up to perhaloalkyl, and 1-2 OH or CO₂R⁶ groups; and
 - (2) aryl or heteroaryl, optionally substituted as set forth below:
 - (a) 1-3 hydroxy groups; (b) 1-5 halo groups; (c) 1-3 C_{1-15} alkyl or alkoxy groups, each optionally substituted with up to five halo and 1-2 hydroxy or CO_2R^6 groups; (d) 1-2 CO_2R^6 , CN, $S(O)_pR^5$ or $CONR^9R^{10}$ groups; (e) NR^9R^{10} ; (f) SCF_3 ; (g) phenyl, heteroaryl or O-phenyl, said group being optionally substituted with 1-5 halo groups, 1-2 OH, CO_2R^6 , CN or $S(O)_nR^5$ groups, and 1-2 C_{1-6} alkyl or alkoxy groups, each optionally substituted with 1-5 halo, up to perhaloalkyl, and 1-2 OH or CO_2R^6 groups;

R² represents H or C₁₋₆alkyl;

R³ represents H or F;

20

25

R⁴ is selected from the group consisting of H, F and OH;

or R³ and R⁴ are taken in combination and represent an oxo group;

 R^5 represents a C_{1-10} alkyl group;

 R^6 represents H or C_{1-10} alkyl, optionally substituted with OH, OC_{1-6} alkyl, CO_2C_{1-6} alkyl, and 1-3 halo groups;

 R^7 represents H, CO_2R^6 , C_{1-6} alkyl optionally substituted with OH, OC_{1-6} alkyl, CO_2R^6 or 1-3 halo groups;

 R^8 and R^9 are independently selected from H and $C_{1\text{-}6}alkyl;$

R¹⁰ is H or is independently selected from:

5

10

15

20

25

30

(a) C₁₋₁₀alkyl, optionally substituted with OH, OC₁₋₆alkyl, CO₂H, CO₂C₁₋₆alkyl, and 1-3 halo groups; (b) aryl or C₁₋₆ alkaryl, each optionally substituted with 1-5 halos and 1-3 members selected from the group consisting of: CN, OH, C₁₋₁₀alkyl and OC₁₋₁₀ alkyl, said alkyl and alkoxy being further optionally substituted with 1-5 halo groups up to perhalo; (c) heterocycle, or C₁₋₆alkyl-heterocycle, optionally substituted with 1-5 halo groups and 1-3 groups selected from: oxo, C₁₋₁₀alkyl and OC₁₋₁₀ alkyl, said alkyl and alkoxy being further optionally substituted with 1-5 halo groups up to perhalo; and (d) heteroaryl or C₁₋₆alkyl-heteroaryl, optionally substituted with 1-5 halo groups and 1-3 groups selected from: C₁₋₁₀alkyl and OC₁₋₁₀ alkyl, said alkyl and alkoxy being further optionally substituted with 1-5 halo groups up to perhalo;

R¹¹ is independently selected from the group consisting of:

(a) C_{1-10} alkyl, optionally substituted with OH, OC₁₋₆alkyl, CO₂H, CO₂C₁₋₆alkyl, and 1-3 halo groups; (b) aryl or C₁₋₆ alkaryl, each optionally substituted with 1-5 halos and 1-3 members selected from the group consisting of: CN, OH, C₁₋₁₀alkyl and OC₁₋₁₀ alkyl, said alkyl and alkoxy being further optionally substituted with 1-5 halo groups up to perhalo; (c) heterocycle, or C₁₋₆alkyl-heterocycle, optionally substituted with 1-5 halo groups and 1-3 groups selected from: oxo, C₁₋₁₀alkyl and OC₁₋₁₀ alkyl, said alkyl and alkoxy being further optionally substituted with 1-5 halo groups up to perhalo; and (d) heteroaryl or C₁₋₆alkyl-heteroaryl, optionally substituted with 1-5 halo groups and 1-3 groups selected from: C₁₋₁₀alkyl and OC₁₋₁₀ alkyl, said alkyl and alkoxy being further optionally substituted with 1-5 halo groups up to perhalo;

Y represents a 4 to 8 membered spirocarbocyclic ring or a spiroheterocyclic ring containing up to three heteroatoms, 0-1 of which are selected from O and S and 0-3 of which are N,

said spirocarbocyclic or spiroheterocyclic ring being optionally substituted on either carbon or nitrogen atoms with up to three groups independently selected as follows:

(a) 1-2 phenyl groups, each being optionally substituted with one to five groups independently selected from the group consisting of: (1) 1-3 hydroxy groups; (2) 1-5 halo groups; (3) 1-3 C_{1-8} alkyl or alkoxy groups, each being further optionally substituted with 1-5 halo or 1-2 OH or CO_2R^6 groups, and (4) 1-2 CO_2R^6 , CN, $S(O)_0R^5$, $CONR^9R^{10}$ or NO_2 groups;

(b) C_{1-10} alkyl optionally substituted with 1-5 groups selected as follows: (i) 1-3 hydroxy groups; (ii) 1 oxo group; (iii) 1-5 halo groups up to perhalo; (iv) 1-3 C_{1-10} alkoxy groups, optionally substituted with 1-5 halo groups up to perhalo, or 1-2 hydroxy or CO_2R^6 groups; (v) 1-2 CO_2R^6 groups; (vi) phenyl, optionally substituted with one to five groups independently selected from the group consisting of: (a) 1-3 hydroxy groups; (b) 1-5 halo groups; (c) 1-3 C_{1-6} alkyl or alkoxy groups, optionally substituted with 1-5 halo groups up to perhalo, or 1-2 hydroxy or CO_2R^6 groups; (d) 1-2 CO_2R^6 , CN, $S(O)_pR^5$, $CONR^9R^{10}$ or NO_2 groups; (e) 1-2 phenyl rings, each of which is optionally substituted as follows: 1-3 C_{1-10} alkyl or alkoxy groups, each being further optionally substituted with 1-5 halo up to perhalo, or 1-2 hydroxy or CO_2R^6 groups;

said spirocarbocyclic or spiroheterocyclic ring being further optionally substituted on a carbon atom with a member selected from the group consisting of:

- (a) $-NR^8-C(O)-NR^9R^{10}$; (b) $-NR^8-CO_2R^{11}$; (c) $-NR^8-C(O)R^{11}$; (d) $-NR^9R^{10}$;
- (e) $-NR^8SO_2R^{11}$; (f) $-SO_2-NR^9R^{10}$; (g) $-C(O)NR^9R^{10}$ and (h) $-OC(O)-NR^9R^{10}$;

and when said ring contains a nitrogen atom, said ring being further optionally substituted on the nitrogen atom with a member selected from the group consisting of:

(a) $-C(O)NR^9R^{10}$; (b) $-CO_2R^{11}$; (c) $C(O)R^{11}$; and (d) $-SO_2R^{11}$;

5

10

15

20

25

30

m and p are independently selected from 0, 1 and 2, and n is an integer from 0 to 6,

when both m and n are zero, Z is selected from 5-tetrazolyl and 5-(2-oxo-1,3,4-oxadiazolyl) and when one of m and n is other than zero, Z is selected from the group consisting of: CO_2R^6 , with R^6 as defined above, 5-tetrazolyl and 5-(2-oxo-1,3,4-oxadiazolyl).

2. A compound in accordance with claim 1 wherein:

R¹ is selected from the group consisting of:

- (1) C_{1-6} alkyl optionally substituted with 1-3 groups selected from: OH, halo, C_{1-3} alkoxy, halo- C_{1-3} alkoxy and phenyl, said phenyl being optionally substituted with 1-3 halo groups, SO_2R^5 , and 1-2 C_{1-3} alkyl or alkoxy groups optionally substituted with 1-3 halo groups, and
- (2) aryl optionally substituted with 1-3 halo groups; 1-2 C_{1-3} alkyl or alkoxy groups, each optionally substituted with 1-3 halo groups; -NR⁹R¹⁰ wherein R⁹ and R¹⁰ are H or methyl; SCF₃ and heteroaryl.
 - 3. A compound in accordance with claim 2 wherein:

R¹ represents phenyl optionally substituted with 1-2 groups selected from Br, Cl; trifluoromethyl and trifluoromethoxy.

- 4. A compound in accordance with claim 1 wherein: X represents CH₂.
- 5. A compound in accordance with claim 1 wherein a and b represent 0 or a represents 1 and b represents 0.
- 6. A compound in accordance with claim 1 wherein:
- Y represents a spiroC₄₋₈cycloalkyl group or a 5-6 membered spiroheterocyclic group containing 1 N atom,

said ring being optionally substituted with a C_{1-6} alkyl group, which is optionally substituted with 1-3 halo groups or 1 Phenyl ring that is optionally substituted with 1-2 halo, 1-2 C_{1-3} alkyl or alkoxy groups, said alkyl and alkoxy substituents being further optionally substituted with 1-3 halo groups.

- 7. A compound in accordance with claim 6 wherein:
 Y represents a spirocyclohexyl or spiropiperidinyl group that is substituted with a C₁₋₄ alkyl group that is optionally substituted with a phenyl ring.
- 8. A compound in accordance with claim 7 wherein:
 Y represents a spirocyclohexyl group substituted with a t-butyl group at the 4 position.
 - 9. A compound in accordance with claim 1 wherein: R^2 is H or C_{1-3} alkyl.
 - 10. A compound in accordance with claim 9 wherein: R² represents H.
- 11. A compound in accordance with claim 1 wherein: R⁷ represents H or methyl.
 - 12. A compound in accordance with claim 11 wherein R⁷ represents H.
- 13. A compound in accordance with claim 1 wherein: n and m represent 0, and Z represents a 5-tetrazolyl group.

35

30

5

15

20

25

14. A compound in accordance with claim 1 wherein: m represents 0, n represents 2, and Z represents a CO_2R^6 group.

- 15. A compound in accordance with claim 1 wherein:
 5 m and n each represent 1, R³ represents OH, R⁴ represents H and Z represents a CO₂R⁶ group.
 - 16. A compound in accordance with claim 1 wherein:

R¹ is selected from the group consisting of:

- (1) C₁₋₆ alkyl optionally substituted with 1-3 groups selected from: OH, halo, C₁₋₃ alkoxy, halo-C₁₋₃alkoxy and phenyl, said phenyl being optionally substituted with 1-3 halo groups, SO₂R⁵, and 1-2 C₁₋₃alkyl or alkoxy groups optionally substituted with 1-3 halo groups, and
 - (2) aryl optionally substituted with 1-3 halo groups; 1-2 C_{1-3} alkyl or alkoxy groups, each optionally substituted with 1-3 halo groups; -NR⁹R¹⁰ wherein R⁹ and R¹⁰ are H or methyl; SCF₃ and heteroaryl; .

X represents CH₂;

10

15

20

25

30

a and b represent 0 or a represents 1 and b represents 0;

Y represents a spiroC₄₋₈cycloalkyl group or a 5-6 membered spiroheterocyclic group containing 1 N atom,

said ring being optionally substituted with a C_{1-6} alkyl group, which is optionally substituted with 1-3 halo groups or 1 Phenyl ring that is optionally substituted with 1-2 halo, 1-2 C_{1-3} alkyl or alkoxy groups, said alkyl and alkoxy substituents being further optionally substituted with 1-3 halo groups;

R² is H or C₁₋₃alkyl;

R⁷ represents H or methyl;

m and n represent 0, and Z represents a 5-tetrazolyl group.

17. A compound in accordance with claim 1 wherein:

R¹ is selected from the group consisting of:

(1) C₁₋₆ alkyl optionally substituted with 1-3 groups selected from: OH, halo, C₁₋₃ alkoxy, halo-C₁₋₃alkoxy and phenyl, said phenyl being optionally substituted with 1-3 halo groups, SO₂R⁵, and 1-2 C₁₋₃alkyl or alkoxy groups optionally substituted with 1-3 halo groups, and

(2) aryl optionally substituted with 1-3 halo groups; 1-2 C_{1-3} alkyl or alkoxy groups, each optionally substituted with 1-3 halo groups; -NR⁹R¹⁰ wherein R⁹ and R¹⁰ are H or methyl; SCF₃ and heteroaryl;

X represents CH₂;

a and b represent 0 or a represents 1 and b represents 0;

Y represents a spiroC₄₋₈cycloalkyl group or a 5-6 membered spiroheterocyclic group containing 1 N atom,

said ring being optionally substituted with a C_{1-6} alkyl group, which is optionally substituted with 1-3 halo groups or 1 Phenyl ring that is optionally substituted with 1-2 halo, 1-2 C_{1-3} alkyl or alkoxy groups, said alkyl and alkoxy substituents being further optionally substituted with 1-3 halo groups;

 R^2 is H or C_{1-3} alkyl;

R⁷ represents H or methyl;

m represents 0, n represents 2, and Z represents a CO_2R^6 group.

15

20

25

30

5

10

- 18. A compound in accordance with claim 1 wherein:
- R¹ is selected from the group consisting of:
- (1) C_{1-6} alkyl optionally substituted with 1-3 groups selected from: OH, halo, C_{1-3} alkoxy, halo- C_{1-3} alkoxy and phenyl, said phenyl being optionally substituted with 1-3 halo groups, SO_2R^5 , and 1-2 C_{1-3} alkyl or alkoxy groups optionally substituted with 1-3 halo groups, and
- (2) aryl optionally substituted with 1-3 halo groups; 1-2 C_{1-3} alkyl or alkoxy groups, each optionally substituted with 1-3 halo groups; -NR⁹R¹⁰ wherein R⁹ and R¹⁰ are H or methyl; SCF₃ and heteroaryl; .

X represents CH₂;

a and b represent 0 or a represents 1 and b represents 0;

Y represents a spiroC₄₋₈cycloalkyl group or a 5-6 membered spiroheterocyclic group containing 1 N atom,

said ring being optionally substituted with a C_{1-6} alkyl group, which is optionally substituted with 1-3 halo groups or 1 Phenyl ring that is optionally substituted with 1-2 halo, 1-2 C_{1-3} alkyl or alkoxy groups, said alkyl and alkoxy substituents being further optionally substituted with 1-3 halo groups;

R² is H or C₁₋₃alkyl;

R⁷ represents H or methyl;

m and n each represent 1, R^3 represents OH, R^4 represents H and Z represents a CO_2R^6 group.

19. A compound in accordance with claim 1 selected from the following table:

| TABLE 1 | | | |
|---|--|--|--|
| Compound | | Compound | |
| CF ₃ O NH N NH | | t-Bu NH NH NH | |
| CF ₃ O OH OH | | we do to | |
| F C C C C C C C C C C C C C C C C C C C | | H _C C CH ₃ | |
| | | HE PHO CH | |

| H _G OH ₃ | |
|---|--|
| HC CH3 HC CH3 OH | H _y C CH _y CH _y C CH _y |
| His China Ch | H ₃ C OH ₃ OH |
| HC CH, CH, CH, CH, CH, CH, CH, CH, CH, C | H ₃ C CH ₃ CH ₃ CH |

| H _C CH ₃ H _C CH ₃ H _C CH ₃ N N N N N N N N N N N N N | H _C CH ₃ |
|--|--|
| of F of F | HC CH4 CONTROL OF THE |
| C C C C C C C C C C C C C C C C C C C | H ₂ C OH ₂ OH H ₂ C OH H ₂ C OH |
| t-Bu OCF ₃ | H ₂ C CH ₃ |

| t-Bu Ch ₃ | HC CH, CO |
|--|--|
| OCF ₃ HIN HO OCH ₃ | mc Car |
| t-Bu CH ₃ NH HO OH | H ² C CH ₂ CH ₂ CH ₃ |
| OCF ₃ N N HO OH | H ₂ C CH ₃ H ₃ C |

| H _S C CH _S ON N N N N N N N N N N N N N N N N N N | H ₃ C CH ₃ H ₃ C CH ₃ N N N N N N N N N N N N N N N N N N N |
|--|---|
| H ₂ C CH ₃ | H ₂ C CH ₃ H ₃ C |
| H ₃ C CH ₃ CO OH | |
| H ₃ C CH ₃ OH | t-Bu OCF ₃ |

| H ₃ C CH ₃ OH | F F C C C C C C C C C C C C C C C C C C |
|-------------------------------------|---|
| t-Bu NO HO OH | t-Bu NH HO OH |
| t-Bu CI HN OH | t-Bu t-Bu ho oh |
| t-Bu CI CI HO OH | CI— |

| H _G C QH ₃ O OH | t-Bu NO HO OH |
|--|--|
| H ₃ C CH ₃ O O O O O O O O O O O O O O O O O O O | H _y C CH _y O N N N N N N N N N N N N N N N N N N |
| H ₃ C CH ₃ | H ₂ C AH ₃ O OH |
| H ₃ C CH ₃ O N N N N N N N N N N N N N N N N N N | H ₂ C CH ₃ O N N N N N N N N N N N N N N N N N N |

| t-Bu CF ₃ | H ₃ C CH ₃ OH |
|---|-------------------------------------|
| t-Bu NO HO OH | t-Bu CI |
| H ₃ C CH ₃ N O N N N N N N N N N N N N N N N N N | t-Bu ho oh |
| H ₃ C CH ₃ NO | t-Bu NO HO OH |

| H ₃ C CH ₃ N O N N N N N N N N N N N N N N N N N | H ₃ C CH ₃ NO NO OH |
|--|--|
| H ₂ C CH ₃ | H ₃ C CH ₃ O O O O O O O O O O O O O O O O O O O |
| H ₃ C CH ₃ CH ₃ CH ₃ N O N N N N N N N N N N N N N N N N N | H ₂ C CH ₃ N O N N N N N N N N N N N N N N N N N |

| t-Bu OH | H ₃ C CH ₃ CH ₃ CO CO COH |
|-------------------------|--|
| t-Bu NH OH | t-Bu CH ₃ |
| t-Bu CH ₃ Br | H ₃ C CH ₃ N O N N N N N N N N N N N N N N N N N |
| t-Bu | H ₃ C CH ₃ N O P P P P P P P P P P P P P P P P P P |

| H ₂ C CH ₃ O N N N N N N N N N N N N N N N N N N | CH ₃ CH ₃ OH | |
|---|---|--|
| H ₂ C CH ₃ N O N N N N N N N N N N N N N N N N N | CH ₃ CH ₉ | |
| H ₃ C CH ₃ CO N N N N N N N N N N N N N N N N N N | CH ₃ CH ₃ NO CH ₃ CH ₃ OO | |

| H ₂ C ₂ CH ₃ | CH ₃ |
|---|---|
| CH ₃ —CH ₃ ₃ —CH ₃ —CH ₃ —CH ₃ CH ₃ —CH ₃ —CH ₃ —CH ₃ —CH ₃ —CH ₃ CH ₃ —CH ₃ — | CH ₃ CH ₃ CH ₃ CH ₃ N N N N N N N N N N N N N N N N N N N |
| CH ₃ CF ₃ CF ₃ CF ₃ N N N N N N N N N N N N N N N N N N N | CH ₃ CH ₈ OH |
| CH ₃ CH ₃ OH | CH ₃ CH ₃ O |

| CH ₃ CH ₃ CH ₃ CH ₃ N N N N N N N N N N N N N N N N N N N | CH ₃ CH ₈ | CI CI CI CI |
|---|---------------------------------|---------------------------------------|
| CH ₉ CH ₉ OH | CH ₃ CH ₃ | F OH |
| CH ₃ CH ₃ | ct. | |
| CH ₃ CH ₃ O CH ₃ N N N N N N N N N N N N N N N N N N N | CH ₃ | 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 |

| | CH ₃ CH ₃ CH ₃ CH ₃ N N N N N N N N N N N N N N N N N N N | CHOHS CHE PER CHES CHES CHES CHES CHES CHES CHES CHES |
|---|---|---|
| | CH ₃ CH ₃ O F F O OH | CHOCK CHE |
| · | CH ₃ CH ₃ CH ₃ OH | CHOCHO CHO |
| | CH ₃ CH ₃ O CH ₃ | 2 2 2 4 2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 |

or a pharmaceutically acceptable salt or solvate thereof

- 20. A pharmaceutical composition comprising a compound in accordance with claim 1 in combination with a pharmaceutically acceptable carrier.
 - 21. A method of treating type 2 diabetes mellitus in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with claim 1 in an amount that is effective to treat said type 2 diabetes mellitus.